交易 Immunovant Inc - IMVT 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.13
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.02237 %(-$0.45)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.02237%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用0.00015 %($0.00)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: 0.00015%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.02237 %
  (-$0.45)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: 0.00015 %
  ($0.00)

主要統計數據

• 前收盤價: 29.55
• 開倉: 29.45
• 1 年變化: 36.47%
• 日區間: 28.74 - 29.45

交易 Immunovant Inc - IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.